+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Immunotherapeutic Strategies for the Treatment of Glioma. Sensitizing Agents for Cancer Resistant to Cell Mediated Immunotherapy

  • ID: 4911836
  • Book
  • July 2020
  • Region: Global
  • 250 Pages
  • Elsevier Science and Technology
1 of 3
Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.
The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.
This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma.
  • Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trials
  • Reviews the challenges and successes of the most promising strategies for brain tumor immunotherapy
  • Provides a foundation for considering novel and combination therapies moving forward
Note: Product cover images may vary from those shown
2 of 3
1. Peptide vaccines
2. Dendritic cell vaccines
3. Heat shock protein vaccines
4. Immune checkpoint blockade
5. Targeting myeloid cells in glioblastoma
6. Oncolytic viruses
7. CAR T cell therapy
8. Mechanisms of immune suppression in glioblastoma patients
9. Immunogenomics in glioblastoma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Lim, Michael
Dr. Lim is a Professor of Neurosurgery, Oncology, Otolaryngology, and Radiation Oncology at Johns Hopkins. He obtained his MD from the Johns Hopkins University School of Medicine. He then completed his residency in Neurosurgery at Stanford University Hospital. Dr. Lim's surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas (including ependymoma), meningioma, pituitary tumors and skull base tumors.
Dr. Lim is the Director of the Brain Tumor Immunotherapy Program at Johns Hopkins. His primary research interest is developing immune-based therapies against brain tumors. His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors. Findings from his laboratory are directed towards translation to novel therapies against brain tumors. In addition to running a laboratory, he also directs the immunotherapy clinical trials program at Johns Hopkins. He currently serves as the principal investigator of several large brain tumor immunotherapy clinical trials based on findings from his laboratory.
Jackson, Christopher
Dr. Jackson is a senior resident in Neurosurgery at Johns Hopkins. He obtained his MD from the Johns Hopkins University School of Medicine. He completed his chief residency in June 2018 and is currently working as a postdoctoral fellow in neuro-oncology. His research interests focus on interactions between brain tumors and the host immune system, particularly local, regional, and systemic mechanisms of immune suppression
Note: Product cover images may vary from those shown
Adroll
adroll